The most common neurological disorders, including neurodegenerative diseases and psychiatric
disorders, have received recent attention with regards to pharmacogenomics and personalized medicine. Here,
we will focus on a neglected neurodegenerative disorder, cerebral ischemic stroke (CIS), and highlight recent
advances in two disorders, Parkinson’s disease (PD) and Alzheimer’s diseases (AD), that possess both similar
and distinct mechanisms in regards to potential therapeutic targets.
In the first part of this review, we will focus primarily on mechanisms that are somewhat specific to each
disorder which are involved in neurodegeneration (i.e., protease pathways, calcium homeostasis, reactive
oxygen species regulation, DNA repair mechanisms, neurogenesis regulation, mitochondrial function, etc.). In
the second part of this review, we will discuss the applications of the genome-wide technology on
pharmacogenomics of mental illnesses including schizophrenia (SCZ), autism spectrum disorders (ASD),
attention deficit hyperactivity disorder (ADHD), and obsessive compulsive disorder (OCD).